{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.3","upperLimit":"8.4","value":"7.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"141"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions; Partial Response (PR): \\>= 30% decrease in the sum of diameters of Target Lesions (compared to baseline) and no new lesions. DoR was defined as the time from the date of first documented response (CR or PR that was subsequently confirmed) until the date of documented progression (PD) or death in the absence of disease progression (by investigator assessment).","dispersionType":"Full Range","groups":[{"description":"Daily single dose of AZD9291 80mg","id":"OG000","title":"AZD9291 80mg"}],"paramType":"MEDIAN","populationDescription":"All patients who received at least 1 dose of study treatment, had measurable disease at baseline according to the independent review of baseline imaging data and had confirmed response.","reportingStatus":"POSTED","timeFrame":"RECIST tumour assessments every 6 weeks from first dose until objective disease progression, up to approximately 11 months (at the time of analysis)","title":"Duration of Response (DoR)","type":"SECONDARY","unitOfMeasure":"months"}